124 related articles for article (PubMed ID: 9001826)
1. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Clin Ther; 1996; 18(6):1093-105. PubMed ID: 9001826
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
[TBL] [Abstract][Full Text] [Related]
3. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
5. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
6. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women.
Notelovitz M; John VA; Good WR
Menopause; 2002; 9(5):343-53. PubMed ID: 12218723
[TBL] [Abstract][Full Text] [Related]
9. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
Shulman LP; Yankov V; Uhl K
Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
[TBL] [Abstract][Full Text] [Related]
11. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
Archer DF; Pickar JH; MacAllister DC; Warren MP
Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
[TBL] [Abstract][Full Text] [Related]
13. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
15. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
Haines C; Yu SL; Hiemeyer F; Schaefers M
Climacteric; 2009 Oct; 12(5):419-26. PubMed ID: 19479489
[TBL] [Abstract][Full Text] [Related]
16. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
20. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
